Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gillian Woollett

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Expert Review of Clinical Pharmacology|December 14, 2012
The rise of the biosimilarMark McCamish, Gillian Woollett
Clinical Pharmacology and Therapeutics|February 10, 2012
The state of the art in the development of biosimilarsMark McCamish, Gillian Woollett
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 8, 2019
Insulins as Drugs or Biologics in the USA: What Difference Does it Make and Why Does it Matter?Kelly George, Gillian Woollett
Managed Care (Langhorne, Pa.)|December 23, 2017
The Self-driving Patient: How Health Care Will Catch UpBruce Pyenson, Gillian Woollett
Mabs|March 29, 2011
Worldwide experience with biosimilar developmentMark McCamish, Gillian Woollett
Drugs|May 23, 2018
Authors' Reply to Pires et al.: "Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes"Hillel P Cohen, Andrew Blauvelt, Robert M Rifkin, et al.
Drugs|March 4, 2018
Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical OutcomesHillel P Cohen, Andrew Blauvelt, Robert M Rifkin, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 17, 2025
Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case StudyMartin Schiestl, Nivedita Roy, Michael Trieb, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Expert Review of Clinical Pharmacology|December 14, 2012
The rise of the biosimilarMark McCamish, Gillian Woollett
Clinical Pharmacology and Therapeutics|February 10, 2012
The state of the art in the development of biosimilarsMark McCamish, Gillian Woollett
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 8, 2019
Insulins as Drugs or Biologics in the USA: What Difference Does it Make and Why Does it Matter?Kelly George, Gillian Woollett
Managed Care (Langhorne, Pa.)|December 23, 2017
The Self-driving Patient: How Health Care Will Catch UpBruce Pyenson, Gillian Woollett
Mabs|March 29, 2011
Worldwide experience with biosimilar developmentMark McCamish, Gillian Woollett
Drugs|May 23, 2018
Authors' Reply to Pires et al.: "Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes"Hillel P Cohen, Andrew Blauvelt, Robert M Rifkin, et al.
Drugs|March 4, 2018
Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical OutcomesHillel P Cohen, Andrew Blauvelt, Robert M Rifkin, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 17, 2025
Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case StudyMartin Schiestl, Nivedita Roy, Michael Trieb, et al.
Pageof 1